Christopher Fox, PhD, is the Vice President of Formulations at IDRI. He has developed multiple vaccine adjuvant formulations for a variety of infectious disease indications, including cGMP manufacturing, clinical testing, and technology transfer to developing country manufacturers. He currently leads efforts to develop a thermostable tuberculosis vaccine as well as scale up adjuvant manufacturing capacity for pandemic influenza preparedness.